Supernus Pharmaceuticals, Inc.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) and Supernus Pharmaceuticals (NASDAQ: SUPN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, earnings, valuation, institutional ownership, risk, analyst recommendations and profitability. Valuation and Earnings This table compares Chugai Pharmaceutical

Wall Street analysts shifted their stances on some of the market's most closely watched names Wednesday, with surprising cuts hitting stocks many investors still consider safe bets and fresh upgrades landing on names that have struggled all year.

The peer is Supernus Pharmaceuticals. The combined business will bear the Supernus name and stock ticker under the terms of a deal announced in August.

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.